Nycomed projects steady earnings despite generic competition
Nycomed SCA SICAR is projecting only a small drop in profits in 2008 even though it faces generic competition for its best selling drug, pantoprazole, a proton pump inhibitor for acid-related gastrointestinal diseases.
18 August 2008